Posted On: 07/14/2014 7:35:21 PM
Post# of 30066
I keep going back to GC's recent comments that a RS may not be necessary in Q4 for up listing.
As several bashers have pointed out, if history repeats itself, AMBS pps will fall dramatically end of week or next week after the conference. But at some point, history will not repeat itself and we've never had catalysts coming up like this before.
So again I say what happens if we don't get to $2+ by Q4 and ONLY get to $1.50?
A near miss would still be an astonishing feat.
Higher highs and higher lows, things just look great. I truly hope they can keep it going.
And I do think GC has been waiting to ink a partnership for LYmPro until tomorrow's data and data at the end of July comes out. A bidding war may indeed happen from the pharma standpoint. The CLIA partner is probably close to being in stone, but tomorrow's data will probably help close the deal.
Good times.
As several bashers have pointed out, if history repeats itself, AMBS pps will fall dramatically end of week or next week after the conference. But at some point, history will not repeat itself and we've never had catalysts coming up like this before.
So again I say what happens if we don't get to $2+ by Q4 and ONLY get to $1.50?
A near miss would still be an astonishing feat.
Higher highs and higher lows, things just look great. I truly hope they can keep it going.
And I do think GC has been waiting to ink a partnership for LYmPro until tomorrow's data and data at the end of July comes out. A bidding war may indeed happen from the pharma standpoint. The CLIA partner is probably close to being in stone, but tomorrow's data will probably help close the deal.
Good times.
(0)
(0)
